These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17174090)

  • 21. Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors.
    Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J
    J Med Chem; 2002 Sep; 45(20):4581-4. PubMed ID: 12238937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.
    Hopkins C; Neuenschwander K; Scotese A; Jackson S; Nieduzak T; Pauls H; Liang G; Sides K; Cramer D; Cairns J; Maignan S; Mathieu M
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4819-23. PubMed ID: 15341931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poststatin, a new inhibitor of prolyl endopeptidase. VII. N-cycloalkylamide analogues.
    Tsuda M; Muraoka Y; Nagai M; Aoyagi T; Takeuchi T
    J Antibiot (Tokyo); 1996 Sep; 49(9):909-20. PubMed ID: 8931725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders.
    Gorrell MD
    Clin Sci (Lond); 2005 Apr; 108(4):277-92. PubMed ID: 15584901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors.
    Steinmetzer T; Dönnecke D; Korsonewski M; Neuwirth C; Steinmetzer P; Schulze A; Saupe SM; Schweinitz A
    Bioorg Med Chem Lett; 2009 Jan; 19(1):67-73. PubMed ID: 19036586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proline-based macrocyclic inhibitors of the hepatitis C virus: stereoselective synthesis and biological activity.
    Chen KX; Njoroge FG; Vibulbhan B; Prongay A; Pichardo J; Madison V; Buevich A; Chan TM
    Angew Chem Int Ed Engl; 2005 Nov; 44(43):7024-8. PubMed ID: 16211639
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.
    Poplawski SE; Lai JH; Li Y; Jin Z; Liu Y; Wu W; Wu Y; Zhou Y; Sudmeier JL; Sanford DG; Bachovchin WW
    J Med Chem; 2013 May; 56(9):3467-77. PubMed ID: 23594271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous (19)F NMR screening of prolyl oligopeptidase and dipeptidyl peptidase IV inhibitors.
    Kichik N; Tarragó T; Giralt E
    Chembiochem; 2010 May; 11(8):1115-9. PubMed ID: 20397181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
    Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.
    Miyazaki Y; Kato Y; Manabe T; Shimada H; Mizuno M; Egusa T; Ohkouchi M; Shiromizu I; Matsusue T; Yamamoto I
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2986-90. PubMed ID: 16540315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).
    Jansen K; Heirbaut L; Verkerk R; Cheng JD; Joossens J; Cos P; Maes L; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    J Med Chem; 2014 Apr; 57(7):3053-74. PubMed ID: 24617858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(l-prolyl-pyrrolidine) amides.
    Wallén EA; Christiaans JA; Jarho EM; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J
    J Med Chem; 2003 Oct; 46(21):4543-51. PubMed ID: 14521416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The natural product berberine is a human prolyl oligopeptidase inhibitor.
    Tarrago T; Kichik N; Seguí J; Giralt E
    ChemMedChem; 2007 Mar; 2(3):354-9. PubMed ID: 17295371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure activity relationship of inhibitors specific for prolyl endopeptidase.
    Yoshimoto T; Tsuru D; Yamamoto N; Ikezawa R; Furukawa S
    Agric Biol Chem; 1991 Jan; 55(1):37-43. PubMed ID: 1368673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design.
    Tully DC; Vidal A; Chatterjee AK; Williams JA; Roberts MJ; Petrassi HM; Spraggon G; Bursulaya B; Pacoma R; Shipway A; Schumacher AM; Danahay H; Harris JL
    Bioorg Med Chem Lett; 2008 Nov; 18(22):5895-9. PubMed ID: 18752942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
    Brigance RP; Meng W; Fura A; Harrity T; Wang A; Zahler R; Kirby MS; Hamann LG
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4395-8. PubMed ID: 20598534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification by 19F NMR of traditional Chinese medicinal plants possessing prolyl oligopeptidase inhibitory activity.
    Tarragó T; Frutos S; Rodriguez-Mias RA; Giralt E
    Chembiochem; 2006 May; 7(5):827-33. PubMed ID: 16628753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
    Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.
    Bogen S; Arasappan A; Pan W; Ruan S; Padilla A; Saksena AK; Girijavallabhan V; Njoroge FG
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4219-23. PubMed ID: 18547808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.